Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

ResMed (RMD) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareMedical Instruments & SuppliesRMD

Closing price · Nov 19, 2026 $237.09 -2.3% on the day · -2.4% over 12 months 52-week range $182.30 – $273.72
Get RMD alerts
Open-market purchases0 insidersno buys · last 12 months
Insiders selling5last 12 months
Reported sales$20.3M37 of 37 recent sales pre-planned (10b5-1)
In 15 seconds

No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.

Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
Latest open-market trade

Sale Witte Jan De, Director sold 429 shares at $237.00 ($102K).

Trade date
Nov 17, 2026
Disclosed to the SEC
Nov 18, 2026
Type
Pre-planned sale, 10b5-1 (code S)

Read the original SEC filing ↗All RMD insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

RMD insider transactions (Form 4)

Open-market purchases and sales. 63 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Nov 18SEC Witte Jan DeDirector Sell Plan 4293,772 held (−10%) $237.00 $102K +0.0% —
Nov 12SEC Michael J. FarrellCEO, Chair Sell Plan 4,993479,803 held (−1%) $235.35 $1.2M +0.7% —
Oct 26SEC Michael J. RiderGeneral Counsel Sell Plan 40012,318 held (−3%) $255.00 $102K -7.0% —
Oct 8SEC Michael J. FarrellCEO, Chair Sell Plan 4,991479,803 held (−1%) $226.33 $1.1M +4.7% —
Sep 10SEC Michael J. FarrellCEO, Chair Sell Plan 4,991466,256 held (−1%) $222.44 $1.1M +6.6% —
Sep 4SEC Peter C. FarrellDirector Sell Plan 97051,803 held (−2%) $234.73 $228K +1.0% —
Aug 11SEC Michael J. FarrellCEO, Chair Sell Plan 4,991466,256 held (−1%) $205.69 $1.0M +15.3% —
Aug 6SEC Peter C. FarrellDirector Sell Plan 8,00052,773 held (−13%) $225.00 $1.8M +5.4% —
Jul 9SEC Michael J. FarrellCEO, Chair Sell Plan 4,991466,223 held (−1%) $218.55 $1.1M +8.5% —
Jun 9SEC Michael J. FarrellCEO, Chair Sell Plan 4,991466,256 held (−1%) $193.96 $968K +22.2% —
May 11SEC Michael J. FarrellCEO, Chair Sell Plan 4,991466,223 held (−1%) $207.82 $1.0M +14.1% —
Apr 9SEC Michael J. FarrellCEO, Chair Sell Plan 4,991466,223 held (−1%) $225.50 $1.1M +5.1% —
Apr 3SEC Brett SandercockCFO Sell Plan 1,00083,495 held (−1%) $224.31 $224K +5.7% —
Apr 2SEC Peter C. FarrellDirector Sell Plan 2,00060,773 held (−3%) $225.00 $450K +5.4% —
Mar 11SEC Michael J. FarrellCEO, Chair Sell Plan 4,991466,223 held (−1%) $251.03 $1.3M -5.6% —
Mar 5SEC Peter C. FarrellDirector Sell Plan 2,00062,773 held (−3%) $260.22 $520K -8.9% —
Mar 3SEC Brett SandercockCFO Sell Plan 1,00084,495 held (−1%) $254.30 $254K -6.8% —
Feb 10SEC Michael J. FarrellCEO, Chair Sell Plan 4,991466,223 held (−1%) $273.78 $1.4M -13.4% —
Feb 6SEC Peter C. FarrellDirector Sell Plan 2,00064,773 held (−3%) $251.31 $503K -5.7% —
Feb 6SEC Michael J. RiderGeneral Counsel Sell Plan 509,691 held (−1%) $260.00 $13K -8.8% —
Feb 3SEC Brett SandercockCFO Sell Plan 1,00085,495 held (−1%) $257.03 $257K -7.8% —
Jan 9SEC Peter C. FarrellDirector Sell Plan 2,00066,773 held (−3%) $248.83 $498K -4.7% —
Jan 8SEC Michael J. FarrellCEO, Chair Sell Plan 4,991466,223 held (−1%) $248.46 $1.2M -4.6% —
Jan 5SEC Brett SandercockCFO Sell Plan 1,00086,495 held (−1%) $241.75 $242K -1.9% —
Jan 5SEC Michael J. RiderGeneral Counsel Sell Plan 509,741 held (−1%) $241.75 $12K -1.9% —
Dec 9SEC Michael J. FarrellCEO, Chair Sell Plan 4,991466,223 held (−1%) $251.41 $1.3M -5.7% —
Dec 4SEC Peter C. FarrellDirector Sell Plan 2,00068,773 held (−3%) $251.47 $503K -5.7% —
Dec 2SEC Brett SandercockCFO Sell Plan 1,00087,495 held (−1%) $244.16 $244K -2.9% —
Dec 2SEC Michael J. RiderGeneral Counsel Sell Plan 509,791 held (−1%) $244.16 $12K -2.9% —
Nov 26SEC Witte Jan DeDirector Sell Plan 2,0554,261 held (−33%) $255.00 $524K -7.0% —
Nov 13SEC Peter C. FarrellDirector Sell Plan 2,00066,110 held (−3%) $252.05 $504K -5.9% —
Nov 13SEC Witte Jan DeDirector Sell Plan 4875,319 held (−8%) $250.25 $122K -5.3% —
Nov 10SEC Michael J. FarrellCEO, Chair Sell Plan 8,011467,866 held (−2%) $249.75 $2.0M -5.1% —
Nov 4SEC Brett SandercockCFO Sell Plan 3,00085,745 held (−3%) $247.54 $743K -4.2% —
Oct 9SEC Michael J. FarrellCEO Sell Plan 8,009467,792 held (−2%) $282.85 $2.3M -16.2% —
Oct 3SEC Brett SandercockCFO Sell Plan 3,00086,745 held (−3%) $274.36 $823K -13.6% —
Oct 2SEC Michael J. RiderGeneral Counsel Sell Plan 10011,327 held (−1%) $274.36 $27K -13.6% —
Historical context

Similar past setups: not applicable. RMD has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with RMD in the Research Lab

RMD has no open-market insider buys in the last 12 months. Try the tools with any setup.

All tools →

Quick backtest: did buys like this beat the market?

Insiders buying
CEO or CFO
Dollar size
Stock before

Tap a setting to see how 6,290 past insider buys did.

Open the full Backtester →

Share price and insider trades

RMD closeInsider buyInsider sale
150200250300DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-01-29EEarnings release filed 2026-04-30EEarnings release filed 2026-07-07EEarnings release filed 2026-08-06Sold $101,673 on 2026-11-17 · Witte Jan DeSold $102,000 on 2026-10-23 · Michael J. RiderSold $227,688 on 2026-09-02 · Peter C. FarrellSold $253,838 on 2026-01-02 · Brett Sandercock, Michael J. RiderSold $254,300 on 2026-03-02 · Brett SandercockSold $256,368 on 2025-12-01 · Brett Sandercock, Michael J. RiderSold $257,030 on 2026-02-02 · Brett SandercockSold $502,940 on 2025-12-03 · Peter C. FarrellSold $515,620 on 2026-02-04 · Michael J. Rider, Peter C. FarrellSold $520,440 on 2026-03-04 · Peter C. FarrellSold $524,025 on 2025-11-25 · Witte Jan DeSold $674,310 on 2026-04-01 · Brett Sandercock, Peter C. FarrellSold $968,064 on 2026-06-08 · Michael J. FarrellSold $1,026,596 on 2026-08-07 · Michael J. FarrellSold $1,037,233 on 2026-05-07 · Michael J. FarrellSold $1,090,771 on 2026-07-07 · Michael J. FarrellSold $1,110,191 on 2026-09-08 · Michael J. FarrellSold $1,125,486 on 2026-04-07 · Michael J. FarrellSold $1,129,637 on 2026-10-07 · Michael J. FarrellSold $1,175,089 on 2026-11-09 · Michael J. FarrellSold $1,252,902 on 2026-03-09 · Michael J. FarrellSold $1,254,796 on 2025-12-08 · Michael J. FarrellSold $1,366,436 on 2026-02-09 · Michael J. FarrellSold $1,737,725 on 2026-01-07 · Michael J. Farrell, Peter C. FarrellSold $1,800,000 on 2026-08-05 · Peter C. Farrell
Bought, 12 months$0
Sold, 12 months$20.3M
Insiders buying0
Insiders selling5

ResMed insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 5 sold $20.3M of RMD stock on the open market; P/E 21.4 vs. a sector median of 25.0.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

RMD insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $9.0M sold (12 trades)Q4 2025Q1 2026: $6.2M sold (11 trades)Q1 2026Q2 2026: $3.8M sold (5 trades)Q2 2026Q3 2026: $5.3M sold (5 trades)Q3 2026Q4 2026: $2.5M sold (4 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$2.5M4
Q3 2026—0$5.3M5
Q2 2026—0$3.8M5
Q1 2026—0$6.2M11
Q4 2025—0$9.0M12

Valuation, profit and volume

P/E (trailing)21.4Sector median 25.0
Market value$31.34BMedical Instruments & Supplies
Profit margin26.9%Revenue growth +8.6%
Volume vs. 50-day0.8×Last 5 sessions

Source: Yahoo Finance, as of Oct 5, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 0 ResMed insiders reported open-market purchases totaling $0, while 5 insiders reported sales totaling $20.3M. 37 of 37 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

RMD earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Aug 6, 2026 +14.4% Sold $2.9M -5.4%S&P +0.5% +8.1%
Jul 7, 2026 +15.8% Sold $968K -5.8%S&P -0.8% +3.0%
Apr 30, 2026 -8.1% Sold $1.8M -3.3%S&P +1.3% -6.8%
Jan 29, 2026 +1.2% Sold $2.0M +0.2%S&P -0.5% -0.6%
Oct 30, 2025 -6.1% Sold $3.1M -2.7%S&P -0.8% +3.9%
Jul 31, 2025 +10.1% None +0.6%S&P -2.0% -1.5%
Apr 23, 2025 +0.5% None +10.3%S&P +3.7% +3.1%
Jan 30, 2025 +10.5% None -6.6%S&P +0.0% -0.9%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

RMD news sentiment trend

Weekly headline tone (positive minus negative headlines) over 13 weeks. Green dots mark weeks with insider buying.

Mixed
Aug 22Sep 12Oct 3Week of 2026-10-17: 1 headlines, 0 positive, 0 negativeWeek of 2026-10-24: 2 headlines, 0 positive, 0 negativeOct 24Week of 2026-11-07: 1 headlines, 0 positive, 0 negativeNov 14
Last 30 days: 4 headlines, 0 positive, 0 negative

Tone is scored from headline wording only. It describes the news, not where the stock is going.

RMD short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

20%40%60%2026-08-26: 84% of volume sold short2026-08-27: 80% of volume sold short2026-08-28: 84% of volume sold short2026-08-31: 83% of volume sold short2026-09-01: 77% of volume sold short2026-09-02: 77% of volume sold short2026-09-03: 68% of volume sold short2026-09-04: 88% of volume sold short2026-09-08: 89% of volume sold short2026-09-09: 83% of volume sold short2026-09-10: 66% of volume sold short2026-09-11: 71% of volume sold short2026-09-14: 84% of volume sold short2026-09-15: 86% of volume sold short2026-09-16: 86% of volume sold short2026-09-17: 78% of volume sold short2026-09-18: 66% of volume sold short2026-09-21: 55% of volume sold short2026-09-22: 56% of volume sold short2026-09-23: 66% of volume sold short2026-09-24: 70% of volume sold short2026-09-25: 69% of volume sold short2026-09-28: 67% of volume sold short2026-09-29: 67% of volume sold short2026-09-30: 67% of volume sold short2026-10-01: 72% of volume sold short2026-10-02: 66% of volume sold short2026-10-05: 65% of volume sold short2026-10-06: 74% of volume sold short2026-10-07: 64% of volume sold short2026-10-08: 63% of volume sold short2026-10-09: 68% of volume sold short2026-10-12: 81% of volume sold short2026-10-13: 80% of volume sold short2026-10-14: 63% of volume sold short2026-10-15: 75% of volume sold short2026-10-16: 81% of volume sold short2026-10-19: 83% of volume sold short2026-10-20: 76% of volume sold short2026-10-21: 77% of volume sold short2026-10-22: 40% of volume sold short2026-10-23: 68% of volume sold short2026-10-26: 64% of volume sold short2026-10-27: 69% of volume sold short2026-10-28: 77% of volume sold short2026-10-29: 51% of volume sold short2026-10-30: 76% of volume sold short2026-11-02: 79% of volume sold short2026-11-03: 78% of volume sold short2026-11-04: 55% of volume sold short2026-11-05: 69% of volume sold short2026-11-06: 74% of volume sold short2026-11-09: 75% of volume sold short2026-11-10: 83% of volume sold short2026-11-11: 63% of volume sold short2026-11-12: 57% of volume sold short2026-11-13: 67% of volume sold short2026-11-16: 71% of volume sold short2026-11-17: 72% of volume sold short2026-11-18: 61% of volume sold shortAug 26Sep 10Sep 24Oct 8Oct 22Nov 5
Latest (Nov 18): 61%20-day average: 67%Prior 2 months: 75%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Members of Congress who traded RMD

From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.

All Congress trades →
MemberTradeTradedReportedSince trade
Thomas H TubervilleSenate Sold $1,001 - $15,000 May 3, 2024Aug 5, 2026 +11.9%
Alan ArmstrongSenate Bought $1,001 - $15,000 Mar 27, 2026Jul 21, 2026 +8.2%

RMD stock news and SEC filings

Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.

Insiders at ResMed

InsiderBoughtSoldLast filingPast buys beat S&PScore
Michael J. FarrellCEO, Chair — $18.0M Nov 13, 2026 — —
Peter C. FarrellDirector — $5.0M Nov 20, 2026 — —
Brett SandercockCFO — $2.8M Apr 3, 2026 — —
Witte Jan DeDirector — $748K Nov 20, 2026 — —
Michael J. RiderGeneral Counsel — $167K Nov 13, 2026 — —
Carol BurtDirector — — Nov 20, 2026 — —
Justin LeongChief Product Officer — — Nov 20, 2026 — —
Aaron BloomerCFO — — Nov 13, 2026 — —
Harjit GillDirector — — Nov 13, 2026 — —
Christopher DeloreficeDirector — — Nov 24, 2025 — —
Ronald R. TaylorDirector — — Nov 24, 2025 — —
Karen DrexlerDirector — — Nov 24, 2025 — —
Desney TanDirector — — Nov 24, 2025 — —
Nicole Mowad-NassarDirector — — Nov 24, 2025 — —
John HernandezDirector — — Nov 24, 2025 — —

Board links: companies that share insiders with RMD

Directors and executives who filed Form 4s for RMD and another company in the last 12 months.

See the map →
  • BDXBecton Dickinson Christopher Delorefice Director here · CFO at BDX · latest filing Dec 1, 2025
  • IQVIqvia Carol Burt Director here · Director at IQV · latest filing Nov 20, 2026
  • OMOutset Medical Karen Drexler Director here · Director at OM · latest filing Dec 2, 2025
  • ULTAUlta Beauty Christopher Delorefice Director here · CFO at ULTA · latest filing Apr 2, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

RMD stock: common questions

Are ResMed insiders buying RMD stock?

No. No ResMed insider reported an open-market purchase of RMD in the past 12 months.

Are ResMed insiders selling RMD stock?

5 insiders reported sales worth $20.3M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is RMD's P/E ratio?

RMD trades at about 21.4 times trailing earnings, compared with a median of 25.0 for the Health Care sector.

What is RMD's 52-week range?

Over the past year RMD has traded between $182.30 and $273.72. It last closed at $237.09 on Nov 19, 2026.